Skip to main content

Arranon FDA Approval History

FDA Approved: Yes (First approved October 28, 2005)
Brand name: Arranon
Generic name: nelarabine
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Acute Lymphoblastic Leukemia, Lymphoma

Arranon (nelarabine) is a chemotherapy agent indicated for the treatment of adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Development timeline for Arranon

Oct 28, 2005Approval Arranon GlaxoSmithKline - Treatment for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Sep 29, 2005Arranon Cancer Drug Receives Advisory Committee Support
Sep 14, 2005FDA Advisory Committee Recommends Accelerated Approval of GlaxoSmithKline's Arranon (nelarabine) Injection

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.